chlorthalidone profile

Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Pathways (1)

chlorthalidone is involved in 1 pathway(s), involving a total of 31 unique proteins and 9 unique compounds

ID Source	ID
PubMed CID	2732
CHEMBL ID	1055
CHEBI ID	3654
SCHEMBL ID	26234
MeSH ID	M0004215

Synonym
CHEMBL1055
chlortalidonum
BRD-A26384407-001-05-3
DIVK1C_000731
KBIO1_000731
MLS000069531 ,
smr000058635
natriuran
renon
zambesil
chlorphthalidolone
chlorothalidone
g 33182
phthalamodine
saluretin
chlorthalidone
g-33182
chlortalidone
2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide
hygroton
hydro-long
isoren
benzenesulfonamide,3-dihydro-1-hydroxy-3-oxo-1h-isoindol-1-yl)-
chlorphthalidone
nsc69200
chlorthalidon
igroton
benzenesulfonamide, 2-chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)-
77-36-1
oksodolin (oxodolin)
nsc-69200
phthalamudine
oradil
SPECTRUM_000146
demi-regroton
BPBIO1_000487
hsdb 3035
benzenesulfonamide, 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1h-isoindol-1-yl)-
clortalidona [inn-spanish]
chlortalidonum [inn-latin]
einecs 201-022-5
brn 0312295
racemic chlorthalidone
thalitone
(+-)-hygroton
oxodoline
urolin
famolin
(+-)-chlorthalidone
oxodolin
nsc 69200
clortalidone [dcit]
2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1h-isoindol-1-yl)benzenesulfonamide
3-hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine
1-oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline
PRESTWICK_759
2-chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1h-isoindol-1-yl)benzenesulfonamide
3-(4'-chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine
1-keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline
CHEBI:3654 ,
NCGC00016317-01
cas-77-36-1
BSPBIO_000441
PRESTWICK2_000351
SPECTRUM5_000743
BSPBIO_002017
2-chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1h-isoindol-1-yl)benzene-1-sulfonamide
bdbm25900
AB00051946
DB00310
chlortalidone (jan/inn)
D00272
thalitone (tn)
chlorthalidone (usp)
hygroton (tn)
IDI1_000731
NCGC00094616-02
NCGC00094616-01
KBIOSS_000626
KBIOGR_001574
KBIO2_005762
KBIO2_000626
KBIO3_001237
KBIO2_003194
SPBIO_002362
SPECTRUM2_000099
PRESTWICK0_000351
SPBIO_000058
PRESTWICK1_000351
SPECTRUM4_000957
SPECTRUM3_000349
NINDS_000731
SPECTRUM1500187
PRESTWICK3_000351
NCGC00094616-04
NCGC00094616-03
HMS2091E12
AC-11367
HMS502E13
HMS1569G03
HMS1920M09
2-chloro-5-(1-hydroxy-3-oxo-2h-isoindol-1-yl)benzenesulfonamide
STK686335
A839067
2-chloro-5-[(1s)-1-hydroxy-3-oxo-isoindolin-1-yl]benzenesulfonamide;chlorthalidone
AKOS005599810
HMS3259H04
HMS2096G03
nsc-756692
pharmakon1600-01500187
nsc756692
tox21_110369
dtxcid902812
dtxsid4022812 ,
HMS2236D07
q0mqd1073q ,
higroton
clortalidone
chlorthalidone [usan:usp]
5-22-07-00602 (beilstein handbook reference)
clortalidona
unii-q0mqd1073q
chlortalidone [inn]
CCG-38917
S3074
2-chloro-5-(1,3-dihydroxy-1h-isoindol-1-yl)benzene-1-sulfonamide
gtpl7147
HMS3372A07
chlorthalidone [usan]
regroton component chlorthalidone
chlorthalidone [hsdb]
chlortalidone [jan]
demi-regroton component chlorthalidone
chlorthalidone component of regroton
chlorthalidone [mi]
chlorthalidone component of tenoretic
clorpres component chlorthalidone
chlortalidone [mart.]
chlorthalidone component of kerledex
chlorthalidone component of combipres
chlorthalidone [usp monograph]
lopressidone component chlorthalidone
chlortalidone [ep monograph]
chlorthalidone component of demi-regroton
tenoretic component chlorthalidone
kerledex component chlorthalidone
chlorthalidone [orange book]
combipres component chlorthalidone
chlorthalidone component of lopressidone
chlortalidone [ep impurity]
chlortalidone [who-dd]
chlorthalidone [vandf]
chlorthalidone [usp-rs]
chlorthalidone component of clorpres
chlortalidone [who-ip]
chlortalidonum [who-ip latin]
HY-15833
NC00690
SCHEMBL26234
NCGC00094616-07
tox21_110369_1
KS-1342
(.+/-.)-hygroton
2-chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1h-isoindol-1-yl)benzenesulfonamide #
2-chloro-5-(1-hydroxy-3-oxo-1h-isoindolinyl)benzenesulfonamide
combipres (salt/mix)
regroton (salt/mix)
oksodolin
(.+/-.)-chlorthalidone
W-104322
2-chloro-5-(1-hydroxy-3-oxoisoindolin-1-yl)benzenesulfonamide
AB00051946_12
OPERA_ID_138
hydroton
chlorthalidone, european pharmacopoeia (ep) reference standard
SR-01000721929-3
sr-01000721929
SR-01000721929-2
chlorthalidone, united states pharmacopeia (usp) reference standard
chlortalidone for peak identification, european pharmacopoeia (ep) reference standard
chlortalidone 1.0 mg/ml in methanol
SBI-0051313.P003
HMS3713G03
Q425289
Z1741981513
mfcd00036257
chlorthalidone (chlortalidone)
74658-80-3
BCP27835
BRD-A26384407-001-15-2
C76474
[(3,5-difluorophenyl)amino](oxo)aceticacid
EN300-18527725
2-chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1h-isoindol-1-yl)-1-benzenesulfonamide
chlortalidone (ep monograph)
chlortalidone (ep impurity)
chlorthalidone (usp-rs)
c03ba04
chlorthalidone (usp monograph)
chlortalidone (mart.)
chlorthalidonechlorthalidone

Excerpt	Reference
"Chlorthalidone (CTD) is a thiazide-like diuretic and an effective antihypertensive drug, yet little data exist to support its use in treating hypertension in individuals with advanced CKD."	( Agarwal, R; Balmes-Fenwick, M; Cramer, AE; Ouyang, F; Sinha, AD; Tu, W, 2020)
"Chlorthalidone (CTD) is an antihypertensive drug and exhibits four crystalline forms: I, II, III and IV. "	( Bonfilio, R; de Araújo, MB; Doriguetto, AC; Leal, JS; Pereira, GR; Santos, OM, 2014)
"Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension. "	( Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017)
"Chlorthalidone is an antihypertensive drug equally effective as amlodipine after kidney transplantation."	( Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017)

Excerpt	Reference
"chlorthalidone has a long terminal half-life in whole blood of 49 h, with peak concentrations occurring 8-10 h after oral dosing."	( Esber, HJ; Farina, PR; Hagopian, M; Hay, N; Keirns, JJ; MacGregor, TR, 1984)
"Chlorthalidone, 12.5-25 mg, has shown cardiovascular benefit, including with MetS and DM."	( Ferdinand, KC, 2013)
"Chlorthalidone has been used sparingly in clinical practice in large measure because it is not readily available in many fixed-dose combination products."	( Sica, DA, 2009)
"Chlorthalidone has been shown to decrease platelet aggregation and vascular permeability and promote angiogenesis in vitro, which is thought to be, in part, the result of reductions in carbonic anhydrase-dependent pathways, including catecholamine-mediated platelet aggregation and downregulation of VEGF-C gene expression."	( Ezer, M; Goldman, A; Kountz, DS; Mikhail, J, 2012)
"Chlorthalidone has proven efficacy to reduce cardiovascular morbidity and mortality, yet it is infrequently used in practice. "	( Bakris, GL; Cushman, WC; Handley, A; Kupfer, S; Sica, D; Song, E; Weber, MA; White, WB, 2012)
"Chlorthalidone has significantly reduced stroke and cardiovascular end points in several landmark trials; however, hydrochlorothiazide remains favored in practice."	( Bergus, GR; Carter, BL; Ernst, ME; Goerdt, CJ; Phillips, BB; Steffensmeier, JJ; Zimmerman, MB, 2006)
"chlorthalidone has a long terminal half-life in whole blood of 49 h, with peak concentrations occurring 8-10 h after oral dosing."	( Esber, HJ; Farina, PR; Hagopian, M; Hay, N; Keirns, JJ; MacGregor, TR, 1984)

Excerpt	Reference
"Chlorthalidone caused an increase in total serum and low density lipoprotein (LDL) cholesterol, but not in high density lipoprotein (HDL) cholesterol."	( Holtzman, E; Rosenthal, T; Segal, P, 1980)

Excerpt	Reference
"chlorthalidone treatment with fasting glucose (P < 0.001)."	( Arnett, DK; Barzilay, JI; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Irvin, MR; Kabagambe, EK; Lynch, AI; Tiwari, HK, 2010)
"Chlorthalidone treatment reduced the high plasma sodium content observed in DOCA-salt rats to the same levels observed in normotensive control groups."	( Bissoli, NS; Cabral, AM; Carvalhinho, FB; Musso, MN; Vasquez, EC, 1992)
"Chlorthalidone treatment reduced arterial hypertension in DOC-salt treated rats (from 160 +/- 7 to 127 +/- 5 mmHg)."	( Bissoli, NS; Cabral, AM; Carvalhinho, FB; Musso, MN; Vasquez, EC, 1990)
"Chlorthalidone treatment resulted in a 90.1 per cent decrease from predicted rates and both dosages yielded similar results."	( Citron, JT; Dolman, LI; Ettinger, B; Livermore, B, 1988)

Class	Description
sulfonamide	An amide of a sulfonic acid RS(=O)2NR'2.
isoindoles
monochlorobenzenes	Any member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Chlorthalidone Action Pathway	31	9

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	0.0040	0.0032	45.4673	12,589.2998	AID2517
USP1 protein, partial	Homo sapiens (human)	Potency	28.1838	0.0316	37.5844	354.8130	AID743255
Microtubule-associated protein tau	Homo sapiens (human)	Potency	7.2680	0.1800	13.5574	39.8107	AID1460; AID1468
Smad3	Homo sapiens (human)	Potency	1.5849	0.0052	7.8098	29.0929	AID588855
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	8.4127	0.0010	22.6508	76.6163	AID1224893
cytochrome P450 2D6	Homo sapiens (human)	Potency	38.9018	0.0010	8.3798	61.1304	AID1645840
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	21.1300	0.0006	27.2152	1,122.0200	AID743219
geminin	Homo sapiens (human)	Potency	4.4719	0.0046	11.3741	33.4983	AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Carbonic anhydrase 12	Homo sapiens (human)	Ki	29.5355	0.0002	1.1043	9.9000	AID1798598; AID1803141; AID367617
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Carbonic anhydrase 1	Homo sapiens (human)	Ki	29.5737	0.0000	1.3726	10.0000	AID1798598; AID1803141; AID367608
Carbonic anhydrase 2	Homo sapiens (human)	IC50 (µMol)	0.6770	0.0002	1.1060	8.3000	AID625236
Carbonic anhydrase 2	Homo sapiens (human)	Ki	29.5504	0.0000	0.7236	9.9200	AID1798598; AID1803141; AID367609
Carbonic anhydrase 3	Homo sapiens (human)	Ki	2.8665	0.0002	2.0102	10.0000	AID1798598; AID367610
Carbonic anhydrase 4	Homo sapiens (human)	Ki	1.3230	0.0002	1.9720	9.9200	AID1798598; AID367611
Carbonic anhydrase 6	Homo sapiens (human)	Ki	1.4875	0.0001	1.4710	9.9200	AID1798598; AID367614
Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)	Ki	1.4260	0.0000	1.2725	9.9000	AID1798598; AID367612
Carbonic anhydrase 7	Homo sapiens (human)	Ki	1.2954	0.0002	1.3737	9.9000	AID1798598; AID367615
Carbonic anhydrase 9	Homo sapiens (human)	Ki	29.5376	0.0001	0.7874	9.9000	AID1798598; AID1803141; AID367616
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Carbonic anhydrase 13	Mus musculus (house mouse)	Ki	1.2972	0.0002	1.3974	9.9000	AID1798598; AID367618
Carbonic anhydrase 14	Homo sapiens (human)	Ki	1.8850	0.0002	1.5099	9.9000	AID1798598; AID367619
Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)	Ki	1.2963	0.0000	1.3412	9.9700	AID1798598; AID367613
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cystic fibrosis transmembrane conductance regulator ATP-binding cassette sub-family C member 7	Homo sapiens (human)	AC50	50.0000	0.0398	15.0025	50.0000	AID743267
Carbonic anhydrase 12	Homo sapiens (human)	Kinact	0.0045	0.0030	0.6674	9.6000	AID328983; AID411536
Carbonic anhydrase 1	Homo sapiens (human)	Kinact	0.3480	0.0100	0.9387	8.6000	AID328974; AID411527
Carbonic anhydrase 2	Homo sapiens (human)	Kinact	0.1380	0.0030	0.7946	10.0000	AID328975; AID411528
Carbonic anhydrase 4	Homo sapiens (human)	Kinact	0.1960	0.0740	2.3934	8.5900	AID328977; AID411530
Carbonic anhydrase 6	Homo sapiens (human)	Kinact	1.3470	0.0009	0.7261	5.3000	AID328980; AID411533
Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)	Kinact	0.9170	0.0200	0.8580	9.4000	AID328978; AID411531
Carbonic anhydrase 7	Homo sapiens (human)	Kinact	0.0028	0.0002	0.2852	5.7300	AID328981; AID411534
Carbonic anhydrase 9	Homo sapiens (human)	Kinact	0.0230	0.0050	0.3197	6.6700	AID328982; AID411535
Carbonic anhydrase 13	Mus musculus (house mouse)	Kinact	0.0150	0.0130	0.5669	8.2300	AID328984; AID411537
Carbonic anhydrase 14	Homo sapiens (human)	Kinact	4.1300	0.0002	1.4495	8.5900	AID328985; AID411538
Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)	Kinact	0.0090	0.0090	0.9231	9.0400	AID328979; AID411532
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
estrous cycle	Carbonic anhydrase 12	Homo sapiens (human)
chloride ion homeostasis	Carbonic anhydrase 12	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 12	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 1	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 2	Homo sapiens (human)
angiotensin-activated signaling pathway	Carbonic anhydrase 2	Homo sapiens (human)
regulation of monoatomic anion transport	Carbonic anhydrase 2	Homo sapiens (human)
secretion	Carbonic anhydrase 2	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 2	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of dipeptide transmembrane transport	Carbonic anhydrase 2	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 2	Homo sapiens (human)
carbon dioxide transport	Carbonic anhydrase 2	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 2	Homo sapiens (human)
response to bacterium	Carbonic anhydrase 3	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 3	Homo sapiens (human)
bicarbonate transport	Carbonic anhydrase 4	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 4	Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of bitter taste	Carbonic anhydrase 6	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 6	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 7	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 7	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 7	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 7	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 7	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 7	Homo sapiens (human)
response to hypoxia	Carbonic anhydrase 9	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 9	Homo sapiens (human)
response to xenobiotic stimulus	Carbonic anhydrase 9	Homo sapiens (human)
response to testosterone	Carbonic anhydrase 9	Homo sapiens (human)
secretion	Carbonic anhydrase 9	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 9	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 14	Homo sapiens (human)
response to bacterium	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 12	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 12	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 1	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
protein binding	Carbonic anhydrase 1	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 1	Homo sapiens (human)
hydro-lyase activity	Carbonic anhydrase 1	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 2	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
protein binding	Carbonic anhydrase 2	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 2	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 3	Homo sapiens (human)
protein binding	Carbonic anhydrase 3	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 3	Homo sapiens (human)
nickel cation binding	Carbonic anhydrase 3	Homo sapiens (human)
protein binding	Carbonic anhydrase 4	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 4	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 4	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 6	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 6	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 7	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 7	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 9	Homo sapiens (human)
protein binding	Carbonic anhydrase 9	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 9	Homo sapiens (human)
molecular function activator activity	Carbonic anhydrase 9	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 14	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 14	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
membrane	Carbonic anhydrase 12	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
cytosol	Carbonic anhydrase 1	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 1	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
cytosol	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
myelin sheath	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 2	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
cytosol	Carbonic anhydrase 3	Homo sapiens (human)
cytosol	Carbonic anhydrase 3	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 3	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
rough endoplasmic reticulum	Carbonic anhydrase 4	Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment	Carbonic anhydrase 4	Homo sapiens (human)
Golgi apparatus	Carbonic anhydrase 4	Homo sapiens (human)
trans-Golgi network	Carbonic anhydrase 4	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
external side of plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
cell surface	Carbonic anhydrase 4	Homo sapiens (human)
membrane	Carbonic anhydrase 4	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
transport vesicle membrane	Carbonic anhydrase 4	Homo sapiens (human)
secretory granule membrane	Carbonic anhydrase 4	Homo sapiens (human)
brush border membrane	Carbonic anhydrase 4	Homo sapiens (human)
perinuclear region of cytoplasm	Carbonic anhydrase 4	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 4	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
extracellular region	Carbonic anhydrase 6	Homo sapiens (human)
extracellular space	Carbonic anhydrase 6	Homo sapiens (human)
cytosol	Carbonic anhydrase 6	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 6	Homo sapiens (human)
extracellular space	Carbonic anhydrase 6	Homo sapiens (human)
mitochondrial matrix	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5A, mitochondrial	Homo sapiens (human)
cytosol	Carbonic anhydrase 7	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 7	Homo sapiens (human)
nucleolus	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
membrane	Carbonic anhydrase 9	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
microvillus membrane	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
membrane	Carbonic anhydrase 14	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
mitochondrial matrix	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
mitochondrion	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 5B, mitochondrial	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1345957	Human carbonic anhydrase 14 (4.2.1.1 Carbonate dehydratases)	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID1345957	Human carbonic anhydrase 14 (4.2.1.1 Carbonate dehydratases)	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1346202	Human carbonic anhydrase 7 (4.2.1.1 Carbonate dehydratases)	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID1346202	Human carbonic anhydrase 7 (4.2.1.1 Carbonate dehydratases)	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1346003	Human carbonic anhydrase 4 (4.2.1.1 Carbonate dehydratases)	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID1346003	Human carbonic anhydrase 4 (4.2.1.1 Carbonate dehydratases)	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1346210	Human carbonic anhydrase 12 (4.2.1.1 Carbonate dehydratases)	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID1346210	Human carbonic anhydrase 12 (4.2.1.1 Carbonate dehydratases)	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328975	Inhibition of human full length carbonic anhydrase 2	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID367612	Inhibition of human recombinant full length CA5A by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367612	Inhibition of human recombinant full length CA5A by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID367610	Inhibition of human recombinant full length CA3 by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367610	Inhibition of human recombinant full length CA3 by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID367609	Inhibition of human recombinant full length CA2 by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367609	Inhibition of human recombinant full length CA2 by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID328980	Inhibition of human full length carbonic anhydrase 6	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID411538	Inhibition of human recombinant CA14 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411538	Inhibition of human recombinant CA14 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID409956	Inhibition of mouse brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496832	Antimicrobial activity against Trypanosoma brucei rhodesiense	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID496830	Antimicrobial activity against Leishmania major	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID411532	Inhibition of human recombinant CA5B by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411532	Inhibition of human recombinant CA5B by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID411530	Inhibition of human recombinant CA4 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411530	Inhibition of human recombinant CA4 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID19424	Partition coefficient (logD7.4)	2001	Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15	ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID496824	Antimicrobial activity against Toxoplasma gondii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID106805	Compound was tested for the inhibition of malate dehydrogenase (MDH) at 200 uM	2003	Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21	Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID411527	Inhibition of human recombinant CA1 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411527	Inhibition of human recombinant CA1 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID367617	Inhibition of human recombinant CA12 catalytic domain by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367617	Inhibition of human recombinant CA12 catalytic domain by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID496818	Antimicrobial activity against Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID411535	Inhibition of human recombinant CA9 catalytic domain by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411535	Inhibition of human recombinant CA9 catalytic domain by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID411537	Inhibition of mouse recombinant CA13 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411537	Inhibition of mouse recombinant CA13 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID411534	Inhibition of human recombinant CA7 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411534	Inhibition of human recombinant CA7 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID27167	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID496825	Antimicrobial activity against Leishmania mexicana	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496828	Antimicrobial activity against Leishmania donovani	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID411533	Inhibition of human recombinant CA6 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411533	Inhibition of human recombinant CA6 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID328974	Inhibition of human full length carbonic anhydrase 1	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID496821	Antimicrobial activity against Leishmania	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID367619	Inhibition of human recombinant full length CA14 by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367619	Inhibition of human recombinant full length CA14 by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID496826	Antimicrobial activity against Entamoeba histolytica	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID367618	Inhibition of mouse recombinant full length CA13 by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367618	Inhibition of mouse recombinant full length CA13 by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID328982	Inhibition of human catalytic domain carbonic anhydrase 9	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID496817	Antimicrobial activity against Trypanosoma cruzi	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID367615	Inhibition of human recombinant full length CA7 by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367615	Inhibition of human recombinant full length CA7 by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID496829	Antimicrobial activity against Leishmania infantum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID411536	Inhibition of human recombinant CA12 catalytic domain by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411536	Inhibition of human recombinant CA12 catalytic domain by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID29363	Dissociation constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID496819	Antimicrobial activity against Plasmodium falciparum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID496831	Antimicrobial activity against Cryptosporidium parvum	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID29813	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID328984	Inhibition of mouse full length carbonic anhydrase 13	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID411531	Inhibition of human recombinant CA5A by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411531	Inhibition of human recombinant CA5A by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID496827	Antimicrobial activity against Leishmania amazonensis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID28681	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID52790	Inhibition of chymotrypsin at 250 uM	2003	Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21	Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID43581	Inhibition of beta-lactamase at 100 uM	2003	Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21	Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID367608	Inhibition of human recombinant full length CA1 by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367608	Inhibition of human recombinant full length CA1 by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID496823	Antimicrobial activity against Trichomonas vaginalis	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496820	Antimicrobial activity against Trypanosoma brucei	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID361985	Lipophilicity, log D of compound at pH 7.4 by microfluidic liquid-liquid extraction method	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Determination of log D via automated microfluidic liquid-liquid extraction.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID328978	Inhibition of human full length carbonic anhydrase 5A	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID328985	Inhibition of human full length carbonic anhydrase 14	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID367616	Inhibition of human recombinant CA9 catalytic domain by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367616	Inhibition of human recombinant CA9 catalytic domain by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID367614	Inhibition of human recombinant full length CA6 by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367614	Inhibition of human recombinant full length CA6 by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID367613	Inhibition of human recombinant full length CA5B by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367613	Inhibition of human recombinant full length CA5B by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID411528	Inhibition of human recombinant CA2 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411528	Inhibition of human recombinant CA2 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID497005	Antimicrobial activity against Pneumocystis carinii	2010	Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6	Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID361986	Lipophilicity, log D of compound at pH 7.4 by shake flask method	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Determination of log D via automated microfluidic liquid-liquid extraction.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID367611	Inhibition of human recombinant full length CA4 by stopped-flow CO2 hydration method	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID367611	Inhibition of human recombinant full length CA4 by stopped-flow CO2 hydration method	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID328979	Inhibition of human full length carbonic anhydrase 5B	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID328981	Inhibition of human full length carbonic anhydrase 7	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID328977	Inhibition of human full length carbonic anhydrase 4	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID328983	Inhibition of human catalytic domain carbonic anhydrase 12	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID411529	Inhibition of human recombinant CA3 by stopped flow CO2 hydration assay	2009	Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2	Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference.
AID411529	Inhibition of human recombinant CA3 by stopped flow CO2 hydration assay	2009	Bioorganic & medicinal chemistry, Feb-01, Volume: 17, Issue:3	Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference.
AID328976	Inhibition of human full length carbonic anhydrase 3	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1798598	CA Inhibition Assay from Article 10.1016/j.bmcl.2008.03.051: \\Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.\\	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct.
AID1803141	CA Inhibition Assay from Article 10.3109/14756366.2011.638921: \\Carbonic anhydrases inhibitory effects of new benzenesulfonamides synthesized by using superacid chemistry.\\	2012	Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 27, Issue:6	Carbonic anhydrases inhibitory effects of new benzenesulfonamides synthesized by using superacid chemistry.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864	HCS microscopy assay (F508del-CFTR)	2016	PloS one, , Volume: 11, Issue:10	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	917 (59.70)	18.7374
1990's	139 (9.05)	18.2507
2000's	168 (10.94)	29.6817
2010's	214 (13.93)	24.3611
2020's	98 (6.38)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	486 (29.72%)	5.53%
Reviews	100 (6.12%)	6.00%
Case Studies	79 (4.83%)	4.05%
Observational	7 (0.43%)	0.25%
Other	963 (58.90%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (82)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Study to Evaluate the Safety and Efficacy of Chlorthalidone in Combination With Amiloride as a Treatment for Elderly Patients With Arterial Hypertension[NCT01191450]	Phase 3	280 participants (Anticipated)	Interventional	2011-08-31	Recruiting
A Randomized, Open-label, Single Dose, Replicate Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy Volunteers[NCT03662620]	Phase 1	67 participants (Actual)	Interventional	2018-10-05	Completed
The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide. A Randomized Controled Trial[NCT04393493]	Phase 2	80 participants (Actual)	Interventional	2017-07-01	Completed
An Observational Study to Evaluate the Efficacy and Safety of Amosartan Plus Tablet in Uncontrolled Essential Hypertension Patients[NCT05462535]		4,785 participants (Actual)	Observational	2018-02-26	Completed
Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect. Comparison Between an ATII Receptor Antagonist and a Diuretic.[NCT03560804]		60 participants (Actual)	Interventional	2014-11-10	Completed
A 12-week, Multi-Center, Randomized Double-Blind, Active Control Parallel Group Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertens[NCT01368536]	Phase 4	975 participants (Actual)	Interventional	2011-05-31	Terminated(stopped due to Based on results from an ALTITUDE study interim analysis, testing aliskiren concomitantly with an ACE inhibitor or ARB, in diabetics with renal impairment)
Evaluation of the Efficacy and Safety of S-amlodipine+Chlorthalidone Combination Therapy and S-amlodipine+Telmisartan Combination Therapy in Hypertensive Patients Inadequately Controlled With Calcium Channel Blocker Monotherapy[NCT03226340]	Phase 4	170 participants (Anticipated)	Interventional	2015-12-02	Recruiting
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control[NCT02521233]	Phase 3	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to Sponsor decision)
An Open-Label, Superiority, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Telmisartan, Amlodipine, and Chlorthalidone Fixed-Dose Combination Versus Telmisartan, Amlodipine, and Hydrochlorothiazide in Elderly Patients With Essential [NCT06041529]	Phase 4	250 participants (Anticipated)	Interventional	2023-09-14	Not yet recruiting
Evaluation of Platelet Effects of Chlorthalidone and Hydrochlorothiazide[NCT02100462]	Phase 4	30 participants (Anticipated)	Interventional	2014-03-31	Recruiting
The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone[NCT02030314]	Phase 4	0 participants (Actual)	Interventional	2013-07-31	Withdrawn(stopped due to The patient population changed. Unable to find patients that meet study criteria)
Efficacy of Chlorthalidone and Hydrochlorothiazide in Combination With Amiloride in Multiple Doses on Blood Pressure in Patients With Primary Hypertension: a Factorial Randomized Controlled Trial.[NCT03928145]	Phase 3	84 participants (Anticipated)	Interventional	2019-11-13	Recruiting
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan Cilexetil + Chlorthalidone (16mg + 12.5mg and 16mg + 25mg) Compared With HYZAAR® in Hypertension Control[NCT02521246]	Phase 3	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to Sponsor decision)
A Randomized,Open-label,Single Dose,Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Comparison to the Co-administration of Twynsta and Hygroton in Healthy Volunteers[NCT02496910]	Phase 1	180 participants (Anticipated)	Interventional	2015-06-30	Completed
A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension[NCT00996281]	Phase 3	837 participants (Actual)	Interventional	2009-10-31	Completed
Night-time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium[NCT02711670]		10 participants (Actual)	Interventional	2014-02-28	Completed
Comparison of Optimal Hypertension Regimens (Part of the Ancestry Informative Markers in Hypertension (AIMHY) Programme - AIMHY-INFORM)[NCT02847338]	Phase 4	1,320 participants (Anticipated)	Interventional	2016-11-30	Recruiting
A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981]	Phase 4	154 participants (Actual)	Interventional	2014-06-30	Active, not recruiting
Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity[NCT04519164]	Phase 4	80 participants (Anticipated)	Interventional	2020-12-01	Recruiting
An Open-label, Multiple-dose, Two-arm Clinical Study to Evaluate the Drug-drug Interaction and Safety of Telmisartan, Amlodipine and/or Chlorthalidone in Healthy Adult Volunteers[NCT02152969]	Phase 1	66 participants (Actual)	Interventional	2014-05-31	Completed
Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate[NCT02665117]		61 participants (Actual)	Interventional	2015-01-31	Completed
A Multicenter, Double-blind, Controlled, Randomized Trial to Evaluate the Association Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension[NCT05920005]	Phase 3	698 participants (Anticipated)	Interventional	2023-08-22	Recruiting
Investigating the Relevance of Skin Sodium and Salt Sensitivity of Blood Pressure in Determining the Response to Anti-Hypertensive Drugs (INTREPID)[NCT05976438]		60 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055]	Phase 4	75 participants (Anticipated)	Interventional	2023-08-25	Recruiting
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans[NCT04467931]		22,213 participants (Actual)	Observational	2020-01-19	Completed
Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus[NCT02644395]	Phase 3	49 participants (Actual)	Interventional	2013-01-18	Completed
Pilot Study to Assess Blockade of Calcium Channels and Sodium Chloride Cotransporters for Physiologic Abnormalities in Liver Transplant Associated Hypertension[NCT05275907]	Phase 4	0 participants (Actual)	Interventional	2022-07-12	Withdrawn(stopped due to Screened participants did not meet inclusion criteria prior to study completion date)
Prevention of Hypertension in Patients With Pre-hypertension: PREVER-prevention Study[NCT00970931]	Phase 3	730 participants (Actual)	Interventional	2010-07-31	Completed
A Comparison Between Diuretics and Angiotensin-receptor Blocker Agents in Patients With Stage I Hypertension: PREVER-treatment Study[NCT00971165]	Phase 3	655 participants (Actual)	Interventional	2010-07-31	Completed
Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial[NCT03923933]	Phase 2	34 participants (Actual)	Interventional	2019-06-18	Completed
Interventional Prospective Cohort Study, Multi-center With Nested Case-control Studies (Family-based and Non-family Based) on Individuals With Resistant Arterial Hypertension.[NCT01083017]		74 participants (Actual)	Observational	2011-04-30	Completed
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study of the TAK 491 Plus Chlorthalidone Fixed-Dose Combination Compared With TAK-491 and Hydrochlorothiazide Coadministration Therapy in Subjects With Moderate to Severe Essential Hypertension[NCT00818883]	Phase 3	609 participants (Actual)	Interventional	2009-02-28	Completed
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Benicar HCT® (Olmesartan Medoxomil-Hydrochlorothiazide) in Subjects With Moderate to Severe Essential Hypertension[NCT00846365]	Phase 3	1,085 participants (Actual)	Interventional	2009-03-31	Completed
A Phase 3, Double-Blind, Randomized, Factorial, Efficacy and Safety Study of TAK 491 Plus Chlorthalidone Fixed-Dose Combination in Participants With Moderate to Severe Hypertension[NCT00847626]	Phase 3	1,711 participants (Actual)	Interventional	2009-01-31	Completed
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 When Co-administered With Chlorthalidone in Subjects With Essential Hypertension[NCT00591773]	Phase 3	551 participants (Actual)	Interventional	2007-09-30	Completed
A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH22162 in Subjects With Essential Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment[NCT02620163]	Phase 3	381 participants (Actual)	Interventional	2015-12-31	Completed
Treatment of Hypertension In Adults With ThiaZIDES: Pragmatic Trial Pilot Study[NCT02591628]		2,027 participants (Actual)	Interventional	2015-08-31	Completed
A One-Year Phase 3, Open-Label Study to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension[NCT00695955]	Phase 3	669 participants (Actual)	Interventional	2007-06-30	Completed
A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension[NCT01033071]	Phase 3	1,071 participants (Actual)	Interventional	2010-01-31	Completed
An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension[NCT00696384]	Phase 3	418 participants (Actual)	Interventional	2007-06-30	Completed
Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD[NCT05171686]	Phase 4	46 participants (Anticipated)	Interventional	2023-02-01	Recruiting
Creating an Active Collaborative Network of Comparative Effectiveness Researchers: A Randomized Study of Initial Diuretic Therapy for Hypertension.[NCT01748123]	Phase 4	0 participants (Actual)	Interventional	2016-08-31	Withdrawn(stopped due to Slow enrollment)
[NCT00000514]	Phase 3	0 participants	Interventional	1984-06-30	Completed
[NCT00000522]	Phase 2	0 participants	Interventional	1985-08-31	Completed
[NCT00000525]	Phase 3	233 participants (Actual)	Interventional	1986-07-31	Completed
Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment[NCT00006294]		37,939 participants (Actual)	Observational	1999-09-30	Completed
[NCT00000499]	Phase 2	0 participants	Interventional	1980-09-30	Completed
Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment[NCT05411991]	Phase 4	104 participants (Anticipated)	Interventional	2022-06-12	Recruiting
Pharmacogenomic Evaluation of Antihypertensive Responses 2[NCT01203852]	Phase 4	839 participants (Actual)	Interventional	2010-08-31	Completed
VA HYPERTENSION SCREENING AND TREATMENT PROGRAM (PILOT STUDY)[NCT00007592]		0 participants	Observational	1989-06-30	Completed
Effect of Antihypertensive Agents on Diastolic Function in Patients With Sleep Apnea: Protocol for a Randomized Controlled Trial[NCT02896621]	Phase 3	69 participants (Actual)	Interventional	2014-12-07	Completed
Efficacy and Safety of the Fixed-dose Combination of Valsartan Plus Chlorthalidone Vs Valsartan or Chlorthalidone Alone in the Treatment of Arterial Hypertension, Open-label, Controlled, Randomized and Multicenter Trial[NCT01850160]	Phase 3	124 participants (Actual)	Interventional	2013-04-30	Completed
A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605[NCT02916602]	Phase 3	340 participants (Actual)	Interventional	2015-04-30	Completed
Safety and Efficacy of Chlorthalidone to Reduce Urinary Calcium Excretion in Adolescents/Yount Adult With Type 1 Diabetes[NCT03325114]	Phase 2	1 participants (Actual)	Interventional	2019-06-28	Terminated(stopped due to COVID restrictions prohibit further study activies)
A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate[NCT01309828]	Phase 3	153 participants (Actual)	Interventional	2011-03-31	Completed
Action to Control Cardiovascular Risk in Diabetes (ACCORD)[NCT00000620]	Phase 3	10,251 participants (Actual)	Interventional	1999-09-30	Completed
A Phase I Clinical Trial to Evaluate the Pharmacokinetic Interactions and Safety Between Telmisartan and Chlorthalidone in Healthy Male Volunteers.[NCT01806363]	Phase 1	60 participants (Anticipated)	Interventional	2012-11-30	Completed
A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With Grades 2 or 3 Essential Hypertension, Who Do Not Achieve Target Blood Pressure F[NCT01456169]	Phase 3	507 participants (Actual)	Interventional	2011-10-31	Completed
Comparative Effectiveness of Ambulatory Blood Pressure Monitoring vs Usual Care for Diagnosing and Managing Hypertension: A Pilot Study[NCT02121041]		28 participants (Actual)	Interventional	2014-05-31	Completed
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control[NCT02493322]	Phase 3	261 participants (Anticipated)	Interventional	2023-04-30	Not yet recruiting
The Effect of Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function in Hypertensive Patients: A Pilot Study[NCT01822860]	Phase 4	0 participants (Actual)	Interventional	2013-03-31	Withdrawn(stopped due to Study subjects were not able to be recruited)
[NCT02841280]	Phase 2	160 participants (Actual)	Interventional	2016-07-31	Completed
[NCT00000513]	Phase 3	0 participants	Interventional	1984-04-30	Completed
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With BENICAR HCT® in Hypertension Control[NCT02483936]	Phase 3	348 participants (Anticipated)	Interventional	2023-04-30	Not yet recruiting
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial[NCT04330300]	Phase 4	2,414 participants (Anticipated)	Interventional	2020-04-30	Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
The Effect of Antihypertensive Agents Over Sleep Apnea: a Randomized Controlled Trial[NCT01896661]	Phase 3	53 participants (Actual)	Interventional	2014-12-31	Completed
CSP #597 - Diuretic Comparison Project[NCT02185417]	Phase 3	13,523 participants (Actual)	Interventional	2016-06-15	Completed
A Randomized, Open-label, 4-way Crossover Single Dose Clinical Trial to Investigate the Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405 When Administered Alone and in Combination in Healthy Male Volunteers[NCT02387554]	Phase 1	33 participants (Actual)	Interventional	2014-08-31	Completed
Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.[NCT04757532]	Phase 1	9 participants (Actual)	Interventional	2020-12-03	Completed
Neural Mechanisms of Thiazide-induced Insulin Resistance[NCT00353652]	Phase 4	166 participants (Actual)	Interventional	2005-01-31	Completed
[NCT00000542]	Phase 3	0 participants	Interventional	1993-08-31	Completed
[NCT02357004]		0 participants (Actual)	Interventional	2015-02-28	Withdrawn(stopped due to Change in priority of interventional protocols)
Confirmatory Study of the Efficacy and Safety of the Combination of Losartan / Chlorthalidone vs Losartan / Hydrochlorothiazide in the Treatment of Patients With Essential Arterial Hypertension[NCT04927299]	Phase 3	190 participants (Anticipated)	Interventional	2022-06-30	Recruiting
Hypertension in Young Adults Trial[NCT05370599]	Phase 2	120 participants (Anticipated)	Interventional	2022-04-15	Recruiting
Spironolactone in Chronic Kidney Disease Enabled by Chlorthalidone: A Pilot Randomized Control Trial[NCT05222191]	Phase 2	24 participants (Anticipated)	Interventional	2022-02-01	Recruiting
Diuretic Use in Hemodialysis Patients With Residual Renal Function: a Proof of Concept Study[NCT05915286]	Phase 4	34 participants (Anticipated)	Interventional	2023-05-29	Recruiting
No Pharmacokinetic Interaction Between Chlorthalidone and Losartan, in Healthy Volunteers Under Fasting Conditions, Administered in Fixed Combination Against Individual Components Administered Jointly and Separately[NCT05090449]	Phase 1	36 participants (Actual)	Interventional	2019-05-01	Completed
A Prospective, Multicentre, Randomized, Open Label, Evaluator-Blind, Phase IV Study to Evaluate the Effect on Improvement of Left Ventricular Hypertrophy by the Control of Blood Pressure in Hypertension Patients With Aortic Valve Disease[NCT03666351]	Phase 4	128 participants (Actual)	Interventional	2018-10-18	Completed
Randomized, Double-blind, Crossover Trial Assessing the Efficacy of Indapamide and Chlorthalidone Compared to Hydrochlorothiazide for the Reduction of Urine Supersaturation for Kidney Stone Prevention[NCT06111885]	Phase 2	99 participants (Anticipated)	Interventional	2024-04-30	Not yet recruiting
Uric Acid and Hypertension in African Americans[NCT00241839]	Phase 3	150 participants (Actual)	Interventional	2005-08-31	Completed
[NCT01750294]	Phase 4	14 participants (Actual)	Interventional	2012-08-31	Completed
Tissue Sodium in Pre-hypertensive Patients[NCT02236520]	Phase 2	71 participants (Actual)	Interventional	2014-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

An Elevation of at Least 0.3 mg/dl of Serum Creatinine From Day One of Intervention Compared With Serum Creatinine at 96hrs After Intervention Started

(NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	Participants (Count of Participants)
Stepped Furosemide	20
Diuretics Combined	24

Change in 24 Hour Urine Output at 96 Hours After Intervention Started From 24 Hour Urine Output One Day Before Intervention Initiation)

Urine output was collected through an urinary catheter and measured and registered by a nurse. The sum of these registrations from 7 am from one day to 7 am of the next day was considered the 24 hour urinary output (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	ml (Mean)
Stepped Furosemide	125
Diuretics Combined	200

Change in Serum Bicarbonate Levels Measured at Day One of Intervention From Serum Bicarbonate Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum bicarbonate levels at day one of intervention minus bicarbonate levels at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mEq/L (Mean)
Stepped Furosemide	2.9
Diuretics Combined	3

Change in Serum Brain Natriuretic Peptide Levels at Baseline From Serum Brain Natriuretic Peptide Levels at 96 Hours After Intervention Started

Baseline levels were defined as the measurement at hospital admission. Calculated as serum brain natriuretic peptide levels at baseline minus serum brain natriuretic peptide levels at 96 hours after intervention started (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	ng/dl (Mean)
Stepped Furosemide	-1344
Diuretics Combined	-1378

Change in Serum Calcium Levels Measured at Day One of Intervention From Serum Calcium Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum calcium levels at day one of intervention minus serum calcium levels at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mg/dl (Mean)
Stepped Furosemide	0.15
Diuretics Combined	-0.05

Change in Serum Chloride Levels Measured at Day One of Intervention From Serum Chloride Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum chloride levels at day one of intervention minus serum chloride levels at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mEq/L (Mean)
Stepped Furosemide	-0.6
Diuretics Combined	-0.4

Change in Serum Copeptin Levels at Day One of Intervention From Serum Copeptin Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum copeptin levels at day one minus serum copeptin levels measured at 96 hrs after intervention started (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	ng/dl (Mean)
Stepped Furosemide	1.1
Diuretics Combined	-16

Change in Serum Creatinine at Day One of Intervention From Serum Creatinine at 96 Hrs After Intervention Started

Calculated as serum creatinine at day one minus serum creatinine at 96 hrs after intervention started (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mg/dl (Mean)
Stepped Furosemide	0.02
Diuretics Combined	0.2

Change in Serum Lactate Levels Measured at Day One of Intervention From Serum Lactate Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum lactate levels at day one of intervention minus serum lactate levels at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mmol/L (Mean)
Stepped Furosemide	0
Diuretics Combined	0.1

Change in Serum Magnesium Levels Measured at Day One of Intervention From Serum Magnesium Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum magnesium levels at day one of intervention minus serum magnesium levels at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mg/dl (Mean)
Stepped Furosemide	0.07
Diuretics Combined	-0.04

Change in Serum Partial Pressure of Carbon Dioxide Measured at Day One of Intervention From Serum Partial Pressure of Carbon Dioxide Measured at 96 Hrs After Intervention Started.

Calculated as serum partial pressure of carbon dioxide at day one of intervention minus serum partial pressure of carbon dioxide at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mmHg (Mean)
Stepped Furosemide	1
Diuretics Combined	3

Change in Serum pH Value Measured at Day One of Intervention From Serum pH Value Measured at 96 Hrs After Intervention Started.

Calculated as serum pH value at day one of intervention minus serum pH value at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	units (Mean)
Stepped Furosemide	0.03
Diuretics Combined	0.02

Change in Serum Potassium Levels Measured at Day One of Intervention From Serum Potassium Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum potassium levels at day one of intervention minus serum potassium levels at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mEq/L (Mean)
Stepped Furosemide	-0.2
Diuretics Combined	-0.4

Change in Serum Sodium Levels Measured at Day One of Intervention From Serum Sodium Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum sodium levels at day one of intervention minus serum sodium levels at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mEq/L (Mean)
Stepped Furosemide	-1.2
Diuretics Combined	0.2

Change in Serum Urea Levels Measured at Day One of Intervention From Serum Urea Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum urea levels at day one of intervention minus serum urea levels at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mg/dl (Mean)
Stepped Furosemide	13
Diuretics Combined	18

In Hospital Mortality Defined as Number of Dead Patients From Day One of Intervention and Before Discharge

(NCT04393493)
Timeframe: From day one of intervention up to discharge, an average of 1 week

Intervention	Participants (Count of Participants)
Stepped Furosemide	4
Diuretics Combined	4

Mortality During Follow up Defined as Number of Dead Patients After Discharge

(NCT04393493)
Timeframe: From day one after discharge up to an average of 161 days

Intervention	Participants (Count of Participants)
Stepped Furosemide	9
Diuretics Combined	12

Number of Days From the Beginning of the Intervention Until Patients Referred Dyspnea Improvement or a Reduction in Supplementary Oxygen Requirements Was Made.

"Dyspnea improvement was referred by the patient as the clinician asked them do you feel more or less difficult to breathe? or if the liters per minute or the fraction of inspired supplementary oxygen necessary maintain an oxygen saturation >90% were diminished" (NCT04393493)
Timeframe: Up to 4 days after intervention started

Intervention	days (Mean)
Stepped Furosemide	4
Diuretics Combined	4

Number of Participants With Renal Function Recovery Defined as a Return to Individual Baseline Serum Creatinine Values

Comparing patient's baseline serum creatinine (previous serum creatinine of 3 months ago and up to a year ago) with creatinine measurements every 24 hours during intervention (4 days) (NCT04393493)
Timeframe: Up to 96 hours after intervention started

Intervention	Participants (Count of Participants)
Stepped Furosemide	8
Diuretics Combined	5

Number of Patients That Achieved >30% Reduction in Brain Natriuretic Compared With Baseline Levels

Baseline levels were defined as the measurement at hospital admission (NCT04393493)
Timeframe: Up to 96 hours after intervention started

Intervention	Participants (Count of Participants)
Stepped Furosemide	5
Diuretics Combined	7

Number of Patients That Required Renal Replacement Therapy of Any Type During Intervention (4 Days).

The requirement of renal replacement therapy was assessed by the nephrology team in charge (NCT04393493)
Timeframe: Up to 96 hours after intervention started

Intervention	Participants (Count of Participants)
Stepped Furosemide	7
Diuretics Combined	6

Number of Patients Whose Interventions Were Stopped Because Clinical Improvement Was Achieved Before 96 Hours as Assessed by de Clinical Judgement of the Medical Team in Charge.

Clinical improvement was referred as remission of symptoms with achievement of 24 hour urine output equal or greater than 3000 milliliters (NCT04393493)
Timeframe: From the beginning of intervention and before 96 hours after that

Intervention	Participants (Count of Participants)
Stepped Furosemide	5
Diuretics Combined	7

Number of Patients With Dyspnea Improvement as Referred by the Patient or Reduction in Supplementary Oxygen Requirements at 96 Hours After Intervention Started

"Dyspnea improvement was referred by the patient as the clinician asked them do you feel more or less difficult to breathe? or if the liters per minute or the fraction of inspired supplementary oxygen necessary to maintain an oxygen saturation >90% were diminished" (NCT04393493)
Timeframe: Up to 96 hours after intervention started

Intervention	Participants (Count of Participants)
Stepped Furosemide	27
Diuretics Combined	27

Number of Patients With Dyspnea Improvement as Referred by the Patient or Reduction in Supplementary Oxygen Requirements Before Day 3 of Intervention

Intervention	Participants (Count of Participants)
Stepped Furosemide	2
Diuretics Combined	7

Number of Patients With Adverse Events, Serious Adverse Events and Death to Assess Safety and Tolerability of Treatment With Valturna and Chlorthalidone or Valturna and Amlodipine Versus Valturna Alone

(NCT01368536)
Timeframe: 12 weeks

Intervention	Participants (Number)
	Adverse Events	Serious Adverse Events	Death
Valturna	62	0	0
Valturna + Amlodipine	54	0	0
Valturna + Chlorthalidone	58	0	0

Percentage of Participants With at Least 1 Adverse Event

An adverse event is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product without regard to causality. (NCT00996281)
Timeframe: From Week 0 (Day 1) to Week 52.

Intervention	percentage of participants (Number)
Azilsartan Medoxomil and Chlorthalidone	78.5
Olmesartan Medoxomil and Hydrochlorothiazide	76.4

Percentage of Participants With Serum Creatinine Elevations Greater Than 50% From Baseline and Greater Than the Upper Limit of Normal (ULN)

Serum creatinine was measured at every visit and evaluated as a laboratory parameter of special interest. The percentage of participants with creatinine increase ≥50% from Baseline and greater than ULN was summarized: - At any visit (includes transient and persistent elevations). - At the Final Visit (includes persistent elevations and participants whose first elevation may have been at the Final Visit). - At least 2 consecutive visits (includes only persistent elevations). (NCT00996281)
Timeframe: Baseline and Week 52

Intervention	percentage of participants (Number)
	At any postbaseline visit	at the Final Visit	≥2 consecutive elevations
Azilsartan Medoxomil and Chlorthalidone	14.2	5.9	5.1
Olmesartan Medoxomil and Hydrochlorothiazide	5.8	1.0	1.2

Chang in Hepatic Fat Measured at Baseline and Week 16

Will be measured using hepatic magnetic resonance imaging at baseline and at week 16 (NCT02665117)
Timeframe: baseline to week 16

Intervention	percent (Mean)
KMgCit + Chlorthalidone	0.31
KCl + Chlorthalidone	1.59

Change in Fasting Plasma Glucose From Week 4 to Week 16

Fasting plasma glucose was measured from venous blood sample at week 4 and week 16 (NCT02665117)
Timeframe: week 4 and week 16

Intervention	mg/dL (Mean)
KMgCit + Chlorthalidone	-5.6
KCl + Chlorthalidone	2.3

Change in FGF23 From Week 4 to Week 16

Will be measured from venous blood sample from week 4 to week 16 (NCT02665117)
Timeframe: week 4 to week 16

Intervention	pg/ml (Mean)
KMgCit + Chlorthalidone	38.1
KCl + Chlorthalidone	13.6

Change in Muscle Magnesium Content Measured at Baseline and Week 16

Will be measured using magnetic resonance imaging at baseline and at week 16 (NCT02665117)
Timeframe: baseline to week 16

Intervention	mM (Mean)
KMgCit + Chlorthalidone	-0.01
KCl + Chlorthalidone	0.02

Change in Diastolic Blood Pressure

(NCT03923933)
Timeframe: Change from Basal to day 28

Intervention	mmHg (Mean)
Placebo	-3.4
Treatment Grup	-13.5

Change in Extracellular Water / Total Body Water Ratio

Decrease in extracellular water / total body water ratio measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28

Intervention	percentage of ECW/TBW (Mean)
Placebo	-0.24
Treatment Grup	-2.92

Change in Extracellular Water

Decrease in extracellular water measured by bioelectrical impedance analysis (NCT03923933)
Timeframe: Change from Basal to day 28

Intervention	litres (Mean)
Placebo	-0.15
Treatment Grup	2.55

Change in Mean Arterial Pressure

decrease in blood pressure compared wit baseline measure (mmhg) (NCT03923933)
Timeframe: Change from Basal to day 28

Intervention	mmHg (Mean)
Placebo	-5.4
Treatment Grup	-18.1

Change in Systolic Blood Pressure

(NCT03923933)
Timeframe: Change from Basal to day 28

Intervention	mmHg (Mean)
Placebo	-10
Treatment Grup	-26.1

Change in the Fractional Excretion of Sodium

Increase in the fractional excretion of sodium compared with the baseline measure (NCT03923933)
Timeframe: Change from Basal to day 28

Intervention	percentage of sodium excreted (Mean)
Placebo	-0.348
Treatment Grup	0.598

Change in Total Body Water

Measured by bioelectrical impedance analysis, compared to the initial measurement (NCT03923933)
Timeframe: Change from Basal to day 28

Intervention	litres (Mean)
Placebo	-0.075
Treatment Grup	-4.36

Change From Baseline in 24-hour Mean Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean diastolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.

Intervention	mmHg (Least Squares Mean)
	Week 6 (n=179; n=162)	Week 10 (n=227; n=230)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	-10.9	-12.6
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-14.7	-15.2

Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean systolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.

Intervention	mmHg (Least Squares Mean)
	Week 6 (n=179, n=162)	Week 10 (n=227, n=230)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	-19.9	-22.4
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-25.7	-26.6

Change From Baseline in Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing) as Measured by Ambulatory Blood Pressure Monitoring.

The change in trough diastolic blood pressure measured at each week indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.

Intervention	mmHg (Least Squares Mean)
	Week 6 (n=179; n=162)	Week 10 (n=227; n=230)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	-10.6	-12.7
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-15.2	-15.1

Change From Baseline in Mean Trough Systolic Blood Pressure (22 to 24 Hours After Dosing) as Measured by Ambulatory Blood Pressure Monitoring.

The change in trough systolic blood pressure measured at each week indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.

Intervention	mmHg (Least Squares Mean)
	Week 6 (n=179, n=162)	Week 10 (n=227, n=230)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	-18.4	-21.4
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-25.7	-25.6

Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean diastolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.

Intervention	mmHg (Least Squares Mean)
	Week 6 (n=179; n=162)	Week 10 (n=227; n=230)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	-11.1	-12.9
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-15.4	-15.8

Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.

Intervention	mmHg (Least Squares Mean)
	Week 6 (n=179; n=162)	Week 10 (n=227; n=230)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	-20.2	-22.8
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-27.0	-27.5

Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing as Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean diastolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.

Intervention	mmHg (Least Squares Mean)
	Week 6 (n=179; n=162)	Week 10 (n=227; n=230)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	-11.1	-12.9
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-15.7	-16.0

Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean diastolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.

Intervention	mmHg (Least Squares Mean)
	Week 6 (n=179; n=162)	Week 10 (n=227; n=230)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	-10.3	-11.9
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-12.8	-13.8

Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean systolic blood pressure measured at each visit indicated including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.

Intervention	mmHg (Least Squares Mean)
	Week 6 (n=179; n=162)	Week 10 (n=227; n=230)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	-18.8	-21.1
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-21.8	-23.8

Change From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing as Measured by Ambulatory Blood Pressure Monitoring

The change in the 12-hour mean systolic blood pressure measured at each visit including final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.

Intervention	mmHg (Least Squares Mean)
	Week 6 (n=179; n=162)	Week 10 (n=227; n=230)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	-20.6	-23.2
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-27.7	-28.0

Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure

The change in sitting trough clinic diastolic blood pressure measured at each week indicated including final visit relative to baseline. Diastolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.

Intervention	mmHg (Least Squares Mean)
	Week 6 (n=295; n=292)	Week 10 (n=295; n=292)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	-11.2	-13.7
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-15.0	-16.4

Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure

The change in sitting trough clinic systolic blood pressure measured at each week indicated including final visit relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00818883)
Timeframe: Baseline, Week 6 and Week 10.

Intervention	mmHg (Least Squares Mean)
	Week 6 (n=295; n=292)	Week 10 (n=295; n=292)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	-29.5	-32.8
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-35.1	-37.8

Percentage of Participants Who Reached Their Trough, Sitting, Clinic Diastolic Blood Pressure Target, Defined as <90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease or <80 mm Hg for Participants With Diabetes or Chronic Kidney Disease.

Percentage of participants who achieve a clinic diastolic blood pressure response measured at each week indicated, defined as <90 mm Hg for participants without diabetes or chronic kidney disease or <80 mm Hg for participants with diabetes or chronic kidney disease. Diastolic blood pressure is the average of the 3 serial trough sitting diastolic blood pressure measurements. (NCT00818883)
Timeframe: Week 2, Week 4, Week 6, Week 8 and Week 10.

Intervention	percentage of participants (Number)
	Week 2 (n=283; n=276)	Week 4 (n=292; n=289)	Week 6 (n=295; n=292)	Week 8 (n=295; n=292)	Week 10 (n=295; n=292)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	41.3	57.4	59.2	72.3	75.0
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	49.1	71.9	76.6	81.4	82.7

Percentage of Participants Who Reached Their Trough, Sitting, Clinic Systolic and Diastolic Blood Pressure Targets, Defined as <140/90 mm Hg Without Diabetes or Chronic Kidney Disease or <130/80 mm Hg With Diabetes or Chronic Kidney Disease

Percentage of participants who achieve both a clinic systolic and diastolic blood pressure response measured at each week indicated, defined as <140/90 mm Hg for participants without diabetes or chronic kidney disease or <130/80 mm Hg for participants with diabetes or chronic kidney disease[GFR <60 mL/min/1.73 m2 or urinary albumin:creatinine ratio (UACR) >200 mg albumin/g creatinine at Screening.] Systolic/diastolic blood pressure is the average of the 3 serial trough sitting systolic/diastolic blood pressure measurements. (NCT00818883)
Timeframe: Week 2, Week 4, Week 6, Week 8 and Week 10.

Intervention	percentage of participants (Number)
	Week 2 (n=283; n=276)	Week 4 (n=292; n=289)	Week 6 (n=295; n=292)	Week 8 (n=295; n=292)	Week 10 (n=295; n=292)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	24.6	45.3	45.9	59.2	62.3
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	27.2	58.6	64.1	72.5	71.5

Percentage of Participants Who Reached Their Trough, Sitting, Clinic Systolic Blood Pressure Targets, Defined as <140 mm Hg for Participants Without Diabetes or Chronic Kidney Disease or <130 mm Hg for Participants With Diabetes or Chronic Kidney Disease

Percentage of participants who achieve a clinic systolic blood pressure response measured at each week indicated, defined as <140mm Hg without diabetes or chronic kidney disease or <130/mm Hg with diabetes or chronic kidney disease. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00818883)
Timeframe: Week 2, Week 4, Week 6, Week 8 and Week 10.

Intervention	percentage of participants (Number)
	Week 2 (n=283; n=276)	Week 4 (n=292; n=289)	Week 6 (n=295; n=292)	Week 8 (n=295; n=292)	Week 10 (n=295; n=292)
Azilsartan Medoxomil 40 mg + Hydrochlorothiazide 12.5 mg QD	34.1	54.7	58.2	65.4	69.9
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	33.2	68.2	71.9	79.7	76.9

Change From Baseline to Week 4 in Trough, Sitting, Clinic Systolic Blood Pressure.

The change in trough systolic blood pressure measured at week 4 relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00846365)
Timeframe: Baseline and Week 4.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-33.0
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-34.1
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-26.9

Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.

The change in trough systolic blood pressure measured at week 8 or final visit relative to baseline. Systolic blood pressure is the average of the 3 serial trough sitting systolic blood pressure measurements. (NCT00846365)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-37.6
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-38.2
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-31.5

Change From Baseline in 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 0 to 12 hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-14.4	-15.4
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-14.8	-16.9
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-10.8	-12.1

Change From Baseline in 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 0 to 12 hours-after-dosing mean Systolic Blood Pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night The mean consists of the average (arithmetic mean) of measurements collected at each time frame and includes all observations recorded over the subsequent 12 hours. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-25.0	-27.1
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-25.5	-28.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-19.2	-21.1

Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 0 to 24-hours-after-dosing mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. . Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average of measurements collected over the subsequent 24 hours. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-13.9	-15.1
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-14.4	-16.4
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-10.5	-12.0

Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.

The change in the 24-hour mean systolic blood pressure at week4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-24.1	-26.4
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-24.4	-27.9
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-18.4	-20.7

Change From Baseline in Daytime Mean (6am to 10pm) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the daytime, while awake (6am to 10pm) mean diastolic blood pressure measured at Week 4 and Week 8relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-14.2	-15.3
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-14.7	-16.6
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-10.7	-12.1

Change From Baseline in Daytime Mean (6am to 10pm) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the daytime, while awake (6am to 10pm) mean systolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night Daytime mean is the average of measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive) included in the 24-hour mean calculations. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-24.5	-26.7
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-25.1	-28.4
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-18.9	-21.0

Change From Baseline in Nighttime Mean (12am to 6am) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the nighttime, while asleep (12am to 6am) mean diastolic blood pressure measured at Week 4 and Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-13.4	-14.9
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-13.3	-15.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-9.6	-11.8

Change From Baseline in Nighttime Mean (12am to 6am) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring

The change in the nighttime, while asleep (12am to 6am) mean systolic blood pressure measured at Week 4 and Week 8 to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive) included in the 24-hour mean calculations. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-22.3	-25.2
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-21.9	-26.3
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-16.6	-19.7

Change From Baseline in Trough Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough systolic blood pressure measured at week 4 and week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-13.4	-14.6
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-14.6	-15.9
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-10.9	-12.0

Change From Baseline in Trough Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=223; n=227; n=219)	Week 8 (n=290; n=278; n=281)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-22.4	-24.9
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-23.6	-26.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-17.4	-19.6

Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure

The change in trough diastolic blood pressure measured at week 4 and week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough sitting diastolic blood pressure measurements. (NCT00846365)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=360; n=347; n=352)	Week 8 (n=363; n=350; n=353)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	-13.6	-16.1
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	-14.2	-16.5
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-10.4	-12.8

Percentage of Participants Who Achieve a Clinic Diastolic AND Systolic Blood Pressure Response, Defined as <140/90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease (CKD) or <130/80 mm Hg for Participants With Diabetes or CKD

Percentage of participants who achieve both a clinic diastolic blood pressure response, defined as <140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) or <130/80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline. (NCT00846365)
Timeframe: Baseline, Week 2, Week 4, Week 6 and Week 8.

Intervention	percentage of participants (Number)
	Week 2 (n=343; n=334; n=345)	Week 4 (n=360; n=347; n=352)	Week 6 (n=362; n=350; n=353)	Week 8 (n=363; n=350; n=353)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	51.3	58.1	68.8	69.4
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	48.5	61.4	65.4	68.9
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	35.9	44.6	55.5	54.7

Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as Defined as <90 mm Hg for Participants Without Diabetes or CKD or <80 mm Hg for Participants With Diabetes or CKD

Percentage of participants who achieve a clinic diastolic blood pressure response, defined as defined as <90 mm Hg for participants without diabetes or CKD or <80 mm Hg for participants with diabetes or CKD at each time frame relative to baseline. (NCT00846365)
Timeframe: Baseline, Week 2, Week 4, Week 6 and Week 8.

Intervention	percentage of participants (Number)
	Week 2 (n=343; n=334; n=345)	Week 4 (n=360; n=347; n=352)	Week 6 (n=362; n=350; n=353)	Week 8 (n=363; n=350; n=353)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	63.6	71.4	77.9	79.9
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	66.2	73.8	76.9	79.1
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	47.8	58.2	66.9	66.0

Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as <140 mm Hg for Participants Without Diabetes or CKD or <130 mm Hg for Participants With Diabetes or CKD

Percentage of participants who achieve a clinic systolic blood pressure response, defined as <140 mm Hg for participants without diabetes or CKD or <130 mm Hg for participants with diabetes or CKD at each time frame relative to baseline. (NCT00846365)
Timeframe: Baseline, Week 2, Week 4, Week 6 and Week 8.

Intervention	percentage of participants (Number)
	Week 2 (n=343; n=334; n=345)	Week 4 (n=360; n=347; n=352)	Week 6 (n=362; n=350; n=353)	Week 8 (n=363; n=350; n=353)
Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD	60.3	66.1	76.8	76.0
Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD	57.2	68.9	73.4	76.0
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	44.9	52.3	64.9	64.6

Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in 24-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00847626)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD	-13.5
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD	-15.0
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-14.9
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD	-17.3
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD	-16.5
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD	-15.9
Chlorthalidone 12.5 mg QD	-5.6
Chlorthalidone 25 mg QD	-6.7
Azilsartan Medoxomil 20 mg QD	-6.8
Azilsartan Medoxomil 40 mg QD	-7.6
Azilsartan Medoxomil 80 mg QD	-8.8

Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in 24-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00847626)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD	-24.0
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD	-26.7
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-26.1
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD	-30.4
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD	-27.9
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD	-28.1
Chlorthalidone 12.5 mg QD	-10.9
Chlorthalidone 25 mg QD	-14.7
Azilsartan Medoxomil 20 mg QD	-11.7
Azilsartan Medoxomil 40 mg QD	-12.6
Azilsartan Medoxomil 80 mg QD	-15.3

Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. (NCT00847626)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD	-13.7
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD	-15.6
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-15.1
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD	-17.6
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD	-16.8
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD	-16.2
Chlorthalidone 12.5 mg QD	-5.6
Chlorthalidone 25 mg QD	-6.5
Azilsartan Medoxomil 20 mg QD	-6.8
Azilsartan Medoxomil 40 mg QD	-7.7
Azilsartan Medoxomil 80 mg QD	-9.1

Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. (NCT00847626)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD	-24.4
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD	-27.7
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-26.7
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD	-31.2
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD	-28.4
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD	-28.5
Chlorthalidone 12.5 mg QD	-10.8
Chlorthalidone 25 mg QD	-14.7
Azilsartan Medoxomil 20 mg QD	-11.7
Azilsartan Medoxomil 40 mg QD	-12.8
Azilsartan Medoxomil 80 mg QD	-15.7

Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. (NCT00847626)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD	-13.6
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD	-15.6
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-15.4
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD	-17.8
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD	-16.8
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD	-16.2
Chlorthalidone 12.5 mg QD	-5.3
Chlorthalidone 25 mg QD	-6.3
Azilsartan Medoxomil 20 mg QD	-6.8
Azilsartan Medoxomil 40 mg QD	-7.6
Azilsartan Medoxomil 80 mg QD	-9.2

Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. (NCT00847626)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD	-12.8
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD	-13.5
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-14.4
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD	-16.2
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD	-15.8
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD	-14.9
Chlorthalidone 12.5 mg QD	-6.0
Chlorthalidone 25 mg QD	-7.1
Azilsartan Medoxomil 20 mg QD	-6.9
Azilsartan Medoxomil 40 mg QD	-7.5
Azilsartan Medoxomil 80 mg QD	-8.0

Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. (NCT00847626)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD	-22.5
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD	-24.0
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-24.3
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD	-28.1
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD	-26.5
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD	-26.3
Chlorthalidone 12.5 mg QD	-11.3
Chlorthalidone 25 mg QD	-14.4
Azilsartan Medoxomil 20 mg QD	-11.8
Azilsartan Medoxomil 40 mg QD	-11.8
Azilsartan Medoxomil 80 mg QD	-14.2

Change From Baseline to Week 8 in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. (NCT00847626)
Timeframe: Baseline and Week 8

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD	-24.6
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD	-28.0
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-27.1
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD	-31.7
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD	-28.5
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD	-28.7
Chlorthalidone 12.5 mg QD	-10.4
Chlorthalidone 25 mg QD	-14.5
Azilsartan Medoxomil 20 mg QD	-11.8
Azilsartan Medoxomil 40 mg QD	-12.7
Azilsartan Medoxomil 80 mg QD	-15.8

Change From Baseline to Week 8 in the Mean Trough Diastolic Blood Pressure (22 to 24 Hours After Dosing), as Measured by Ambulatory Blood Pressure Monitoring.

The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00847626)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD	-13.3
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD	-15.0
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-13.5
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD	-17.3
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD	-16.5
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD	-16.1
Chlorthalidone 12.5 mg QD	-6.5
Chlorthalidone 25 mg QD	-7.5
Azilsartan Medoxomil 20 mg QD	-7.9
Azilsartan Medoxomil 40 mg QD	-7.3
Azilsartan Medoxomil 80 mg QD	-8.9

Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pairwise Analysis)

The change in trough systolic blood pressure in black participants as measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00847626)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD	-27.2
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD	-25.4
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-21.5
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD	-31.9
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD	-24.8
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD	-24.4
Chlorthalidone 12.5 mg QD	-12.2
Chlorthalidone 25 mg QD	-23.4
Azilsartan Medoxomil 20 mg QD	-10.7
Azilsartan Medoxomil 40 mg QD	-11.0
Azilsartan Medoxomil 80 mg QD	-9.9

Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring in Black Participants (Pooled Analysis)

The change in trough systolic blood pressure in black subjects measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00847626)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg or 80 mg/Chlorthalidone 25 mg QD	-28.2
Chlorthalidone 25 mg QD	-23.4
Azilsartan Medoxomil 80 mg QD	-9.9

Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure

The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the average of the 3 serial trough clinic sitting diastolic blood pressure measurements. (NCT00847626)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD	-14.4
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD	-15.5
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-15.6
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD	-17.0
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD	-16.9
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD	-18.5
Chlorthalidone 12.5 mg QD	-7.4
Chlorthalidone 25 mg QD	-9.2
Azilsartan Medoxomil 20 mg QD	-6.7
Azilsartan Medoxomil 40 mg QD	-9.2
Azilsartan Medoxomil 80 mg QD	-9.9

Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure

The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 serial trough sitting systolic blood pressure measurements. (NCT00847626)
Timeframe: Baseline and Week 8

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD	-33.8
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD	-37.0
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-36.8
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD	-39.5
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD	-36.9
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD	-40.1
Chlorthalidone 12.5 mg QD	-21.1
Chlorthalidone 25 mg QD	-27.1
Azilsartan Medoxomil 20 mg QD	-19.8
Azilsartan Medoxomil 40 mg QD	-23.3
Azilsartan Medoxomil 80 mg QD	-24.2

Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pairwise Analysis)

The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00847626)
Timeframe: Baseline and Week 8.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD	-22.9
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD	-26.3
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	-24.4
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD	-29.8
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD	-26.3
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD	-28.0
Chlorthalidone 12.5 mg QD	-12.7
Chlorthalidone 25 mg QD	-15.9
Azilsartan Medoxomil 20 mg QD	-12.1
Azilsartan Medoxomil 40 mg QD	-12.8
Azilsartan Medoxomil 80 mg QD	-15.1

Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg or 80 mg/Chlorthalidone 25 mg QD	-28.9
Chlorthalidone 25 mg QD	-15.9
Azilsartan Medoxomil 80 mg QD	-15.1

Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response at Week 8, Defined as Clinic Diastolic Blood Pressure <90 mm Hg and/or a Reduction of ≥10 mm Hg From Baseline.

Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 8, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the average of the 3 serial trough sitting clinic diastolic blood pressure measurements. (NCT00847626)
Timeframe: Baseline and Week 8.

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD	89.6
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD	89.5
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	87.6
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD	94.8
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD	90.1
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD	96.8
Chlorthalidone 12.5 mg QD	63.9
Chlorthalidone 25 mg QD	78.8
Azilsartan Medoxomil 20 mg QD	60.6
Azilsartan Medoxomil 40 mg QD	71.1
Azilsartan Medoxomil 80 mg QD	74.7

Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response at Week 8, as Defined by Clinic Systolic Blood Pressure <140 mm Hg and/or a Reduction of ≥20 mm Hg From Baseline.

Percentage of participants who achieve a clinic systolic blood pressure response measured at week 8, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the average of the 3 serial trough sitting clinic systolic blood pressure measurements. (NCT00847626)
Timeframe: Baseline and Week 8

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD	86.4
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD	88.9
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	90.3
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD	93.5
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD	86.8
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD	94.9
Chlorthalidone 12.5 mg QD	56.1
Chlorthalidone 25 mg QD	76.9
Azilsartan Medoxomil 20 mg QD	53.5
Azilsartan Medoxomil 40 mg QD	64.5
Azilsartan Medoxomil 80 mg QD	66.7

Percentage of Participants Who Achieve Both a Clinic Systolic and Diastolic Blood Pressure Response at Week 8.

Percentage of participants who achieve both a clinic systolic and diastolic blood pressure response measured at week 8, defined as systolic blood pressure less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg AND diastolic blood pressure less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg . Systolic/diastolic blood pressure is based on the average of the 3 serial trough clinic sitting systolic/diastolic blood pressure measurements. (NCT00847626)
Timeframe: Baseline and Week 8.

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 20 mg/Chlorthalidone 12.5 mg QD	83.1
Azilsartan Medoxomil 20 mg/Chlorthalidone 25 mg QD	84.3
Azilsartan Medoxomil 40 mg/Chlorthalidone 12.5 mg QD	84.8
Azilsartan Medoxomil 40 mg/Chlorthalidone 25 mg QD	91.0
Azilsartan Medoxomil 80 mg/Chlorthalidone 12.5 mg QD	82.8
Azilsartan Medoxomil 80 mg/Chlorthalidone 25 mg QD	93.0
Chlorthalidone 12.5 mg QD	45.8
Chlorthalidone 25 mg QD	67.9
Azilsartan Medoxomil 20 mg QD	39.4
Azilsartan Medoxomil 40 mg QD	55.3
Azilsartan Medoxomil 80 mg QD	62.3

Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. (NCT00591773)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-18.82
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-18.99
Chlorthalidone 25 mg QD	-7.79

Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. (NCT00591773)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-32.53
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-31.97
Chlorthalidone 25 mg QD	-15.73

Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure.

The change in mean trough clinic sitting diastolic blood pressure measured at final visit or week 6 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. (NCT00591773)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-16.18
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-15.98
Chlorthalidone 25 mg QD	-8.93

Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure.

The change in mean trough clinic sitting systolic blood pressure measured at final visit or week 6 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements. (NCT00591773)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-36.16
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-34.44
Chlorthalidone 25 mg QD	-21.76

Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. (NCT00591773)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-19.06
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-19.20
Chlorthalidone 25 mg QD	-7.53

Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in the 12-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. (NCT00591773)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-33.02
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-32.45
Chlorthalidone 25 mg QD	-15.50

Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00591773)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-18.28
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-18.49
Chlorthalidone 25 mg QD	-7.99

Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT00591773)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-31.72
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-31.30
Chlorthalidone 25 mg QD	-15.85

Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. (NCT00591773)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-17.05
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-17.06
Chlorthalidone 25 mg QD	-8.89

Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. (NCT00591773)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-29.52
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-29.43
Chlorthalidone 25 mg QD	-16.59

Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean diastolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00591773)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-18.78
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-19.04
Chlorthalidone 25 mg QD	-9.36

Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.

The change in trough mean systolic blood pressure measured at week 6 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough mean is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT00591773)
Timeframe: Baseline and Week 6.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	-30.73
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	-30.16
Chlorthalidone 25 mg QD	-16.69

Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg

Percentage of participants who achieve a clinic diastolic blood pressure response measured at week 6 , defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. (NCT00591773)
Timeframe: Baseline and Week 6.

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	92.7
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	90.3
Chlorthalidone 25 mg QD	78.1

Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg

Percentage of participants who achieve a clinic systolic blood pressure response measured at week 6, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements. (NCT00591773)
Timeframe: Baseline and Week 6.

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	87.7
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	84.1
Chlorthalidone 25 mg QD	63.5

Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response.

Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at week 6, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the 3 sitting blood pressure measurements. (NCT00591773)
Timeframe: Baseline and Week 6.

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 40 mg QD and Chlorthalidone 25 mg QD	84.9
Azilsartan Medoxomil 80 mg QD and Chlorthalidone 25 mg QD	80.7
Chlorthalidone 25 mg QD	58.4

Change From Baseline in Sitting Clinic Diastolic Blood Pressure - Cohort 1.

The change between sitting clinic diastolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit. (NCT00695955)
Timeframe: 52 weeks.

Intervention	mmHg (Mean)
	Week 4	Week 8	Week 12	Week 16	Week 26	Week 36	Week 46	Week 56	Final Visit
Cohort 1	-8.9	-11.0	-15.9	-18.7	-18.6	-19.9	-19.8	-18.4	-16.5

Change From Baseline in Sitting Clinic Diastolic Blood Pressure - Cohort 2.

Intervention	mmHg (Mean)
	Week 4	Week 8	Week 12	Week 16	Week 26	Week 36	Week 46	Week 56	Final Visit
Cohort 2	-10.6	-12.3	-16.8	-18.2	-17.7	-16.2	-17.2	-17.9	-16.2

Change From Baseline in Sitting Clinic Systolic Blood Pressure - Cohort 1.

The change between sitting clinic systolic blood pressure measured at each week assessed relative to the baseline measurement. Mean calculated by using the average (arithmetic mean) of 3 measurements performed at each visit. (NCT00695955)
Timeframe: 52 weeks

Intervention	mmHg (Mean)
	Week 4	Week 8	Week 12	Week 16	Week 26	Week 36	Week 46	Week 56	Final Visit
Cohort 1	-10.1	-13.1	-21.5	-25.4	-26.3	-27.3	-28.1	-25.2	-22.1

Change From Baseline in Sitting Clinic Systolic Blood Pressure - Cohort 2

Intervention	mmHg (Mean)
	Week 4	Week 8	Week 12	Week 16	Week 26	Week 36	Week 46	Week 56	Final Visit
Cohort 2	-14.4	-17.5	-23.8	-26.2	-24.8	-22.5	-23.8	-24.2	-22.7

Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 1.

Treatment-emergent adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after the last dose of study drug, or if a serious adverse event, within 30 days after the last dose of study drug. (NCT00695955)
Timeframe: 56 weeks.

Intervention	participants (Number)
	Number of Participants	Percentage of Participants
Cohort 1	267	73.8

Number of Participants Reporting One or More Treatment-emergent Adverse Events From Day 1 Through End of the Study - Cohort 2.

Intervention	participants (Number)
	Number of Participants	Percentage of Participants
Cohort 2	241	78.5

Change From Baseline in 24-hour Mean Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-19.4
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-20.7
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-16.2

Change From Baseline in 24-hour Mean Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in 24-hour mean systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing. (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-33.9
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-36.3
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-27.5

Change From Baseline in Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive). (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-20.1
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-21.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-17.0

Change From Baseline in Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in daytime (6am to 10pm) mean systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 AM (inclusive) and 10 PM (exclusive). (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-35.3
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-37.9
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-28.8

Change From Baseline in Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in the mean nighttime (12am to 6am) diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Mean nighttime is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive). (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-17.5
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-18.0
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-14.0

Change From Baseline in Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in the mean nighttime (12am to 6am) systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Mean nighttime is the average (arithmetic mean) of measurements recorded between the hours of 12 AM (inclusive) and 6 AM (exclusive). (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-29.6
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-31.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-23.9

Change From Baseline in Mean Trough Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in trough diastolic blood pressure measured at week 12 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-19.8
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-20.2
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-16.0

Change From Baseline in Mean Trough Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.

The change in trough systolic blood pressure measured at week 12 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Trough is the average of all measurements recorded from 22 to 24 hours after dosing. (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-32.9
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-34.9
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-25.9

Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.

The change in the mean 12 hour diastolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements. (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-20.4
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-22.2
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-17.5

Change From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.

The change in the mean 12 hour systolic blood pressure measured at week 12 or final visit relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements. (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-36.2
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-38.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-29.7

Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.

The change in sitting trough clinic systolic blood pressure measured at week 12 or final visit relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-42.5
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-44.0
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-37.1

Change From Baseline in the Mean Diastolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.

The change from baseline for each hour interval of the 24-hour ambulatory blood pressure monitoring measured at week 12 or final visit. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The mean consists of the average (arithmetic mean) of measurements collected at each hour. (NCT01033071)
Timeframe: Baseline and Week 12.

Intervention	mmHg (Least Squares Mean)
	0 to 1 Hour (n=232; n=212; n=237)	1 to 2 Hour (n=232; n=214; n=238)	2 to 3 Hour (n=232; n=214; n=238)	3 to 4 Hour (n=232; n=214; n=238)	4 to 5 Hour (n=232; n=214; n=238)	5 to 6 Hour (n=232; n=214; n=238)	6 to 7 Hour (n=232; n=214; n=238)	7 to 8 Hour (n=232; n=214; n=238)	8 to 9 Hour (n=232; n=214; n=238)	9 to 10 Hour (n=232; n=214; n=238)	10 to 11 Hour (n=232; n=214; n=238)	11 to 12 Hour (n=232; n=214; n=238)	12 to 13 Hour (n=232; n=214; n=238)	13 to 14 Hour (n=232; n=214; n=238)	14 to 15 Hour (n=232; n=214; n=238)	15 to 16 Hour (n=232; n=214; n=238)	16 to 17 Hour (n=232; n=214; n=238)	17 to 18 Hour (n=231; n=214; n=238)	18 to 19 Hour (n=232; n=214; n=238)	19 to 20 Hour (n=232; n=214; n=238)	20 to 21 Hour (n=232; n=214; n=238)	21 to 22 Hour (n=232; n=214; n=238)	22 to 23 Hour (n=232; n=214; n=238)	23 to 24 Hour (n=232; n=214; n=238)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-18.2	-18.8	-21.2	-20.8	-21.7	-20.9	-20.8	-20.5	-20.7	-21.0	-19.7	-19.3	-19.2	-19.6	-18.9	-17.8	-17.2	-16.6	-17.4	-17.8	-16.7	-17.8	-19.5	-20.2
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-20.4	-20.9	-23.4	-23.7	-23.7	-23.6	-22.0	-21.9	-21.5	-21.9	-20.7	-21.2	-20.3	-19.5	-19.7	-18.6	-16.9	-17.1	-18.1	-18.5	-18.4	-18.5	-19.6	-21.0
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-15.2	-15.9	-17.7	-18.2	-17.9	-19.0	-18.0	-17.7	-17.9	-18.3	-16.7	-17.0	-16.0	-15.3	-15.4	-14.5	-13.9	-13.2	-14.3	-13.8	-13.9	-14.7	-15.6	-16.4

Change From Baseline in the Mean Systolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.

Intervention	mmHg (Least Squares Mean)
	0 to 1 Hour (n=232; n=212; n=237)	1 to 2 Hour (n=232; n=214; n=238)	2 to 3 Hour (n=232; n=214; n=238)	3 to 4 Hour (n=232; n=214; n=238)	4 to 5 Hour (n=232; n=214; n=238)	5 to 6 Hour (n=232; n=214; n=238)	6 to 7 Hour (n=232; n=214; n=238)	7 to 8 Hour (n=232; n=214; n=238)	8 to 9 Hour (n=232; n=214; n=238)	9 to 10 Hour (n=232; n=214; n=238)	10 to 11 Hour (n=232; n=214; n=238)	11 to 12 Hour (n=232; n=214; n=238)	12 to 13 Hour (n=232; n=214; n=238)	13 to 14 Hour (n=232; n=214; n=238)	14 to 15 Hour (n=232; n=214; n=238)	15 to 16 Hour (n=232; n=214; n=238)	16 to 17 Hour (n=232; n=214; n=238)	17 to 18 Hour (n=231; n=214; n=238)	18 to 19 Hour (n=232; n=214; n=238)	19 to 20 Hour (n=232; n=214; n=238)	20 to 21 Hour (n=232; n=214; n=238)	21 to 22 Hour (n=232; n=214; n=238)	22 to 23 Hour (n=232; n=214; n=238)	23 to 24 Hour (n=232; n=214; n=238)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-33.6	-33.4	-36.7	-36.6	-36.8	-37.2	-36.3	-37.2	-37.3	-36.9	-36.1	-35.2	-34.8	-34.1	-33.4	-30.9	-29.6	-28.5	-29.5	-29.7	-28.2	-30.6	-32.9	-33.1
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-36.2	-36.4	-39.3	-40.3	-40.8	-41.2	-38.6	-38.5	-38.1	-38.0	-37.6	-38.2	-36.2	-35.3	-35.0	-32.9	-31.1	-30.8	-31.9	-32.5	-31.2	-32.8	-34.0	-35.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-26.8	-27.5	-30.0	-29.6	-30.1	-31.5	-29.8	-29.7	-30.5	-30.8	-29.4	-29.3	-27.7	-26.4	-26.2	-25.3	-24.5	-23.1	-24.3	-23.5	-23.0	-24.6	-25.9	-26.1

Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure.

The change in sitting trough clinic diastolic blood pressure measured at each week indicated relative to baseline. Trough blood pressure is the average (arithmetic mean) of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4, Week 8 and Week 12.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=343; n=330; n=352)	Week 8 (n=344; n=330; n=353)	Week 12 (n=344; n=330; n=354)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-14.9	-17.0	-18.8
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-15.8	-17.7	-20.5
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-11.7	-13.9	-16.4

Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.

The change in sitting trough clinic systolic blood pressure measured at each week indicated relative to baseline. Trough blood pressure is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4 and Week 8.

Intervention	mmHg (Least Squares Mean)
	Week 4 (n=343; n=330; n=352)	Week 8 (n=344; n=330; n=353)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	-34.7	-39.1
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	-36.7	-39.4
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	-29.7	-33.5

Percent of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline and Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.

Percentage of participants who achieve both a clinic diastolic and systolic blood pressure response measured at each week indicated, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg AND less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Diastolic and systolic blood pressure is based on the arithmetic mean of the non-missing values of the 3 serial trough sitting blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4, Week 8 and Week 12.

Intervention	percent of participants (Number)
	Week 4 (n=343; n=330; n=352)	Week 8 (n=344; n=330; n=353)	Week 12 (n=344; n=330; n=354)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	81.3	88.1	91.3
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	84.8	87.3	92.4
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	74.4	81.0	84.7

Percentage of Participants Who Reached Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.

Percentage of participants who achieve a clinic diastolic blood pressure response measured at each week indicated, defined as less than 90 mm Hg and/or reduction from baseline of greater than or equal to 10 mm Hg. Diastolic blood pressure is the arithmetic mean of the non-missing values of the 3 serial trough sitting diastolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4, Week 8 and Week 12.

Intervention	percentage of participants (Number)
	Week 4 (n=343; n=330; n=352)	Week 8 (n=344; n=330; n=353)	Week 12 (n=344; n=330; n=354)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	89.2	90.7	94.5
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	89.7	90.9	95.8
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	85.2	87.8	91.5

Percentage of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline.

Percentage of participants who achieve a clinic systolic blood pressure response measured at each week indicated, defined as less than 140 mm Hg and/or reduction from baseline of greater than or equal to 20 mm Hg. Systolic blood pressure is the arithmetic mean of the non-missing values of the 3serial trough sitting systolic blood pressure measurements. (NCT01033071)
Timeframe: Baseline, Week 4, Week 8 and Week 12.

Intervention	percentage of participants (Number)
	Week 4 (n=343; n=330; n=352)	Week 8 (n=344; n=330; n=353)	Week 12 (n=344; n=330; n=354)
Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD	87.8	93.3	93.0
Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD	90.0	92.4	94.2
Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD	79.8	85.6	89.3

Change From Double-blind Baseline (Week 26) in Sitting Clinic Diastolic Blood Pressure to Week 32

The change in sitting clinic diastolic blood pressure measured at final visit or week 32 from Double-blind Baseline/Week 26. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. Each participant's blood pressure at the Final Visit/Week 26 of the open-label phase represented their Baseline blood pressure for the double-blind reversal phase. (NCT00696384)
Timeframe: Double-blind Baseline (Week 26) and Week 32.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil QD - Double Blind Reversal Phase	0.14
Placebo QD - Double Blind Reversal Phase	7.92

Change From Double-blind Baseline (Week 26) in Sitting Clinic Systolic Blood Pressure to Week 32

The change in sitting clinic systolic blood pressure measured at final visit or week 32 from Double-blind Baseline/Week 26.. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements. Each participant's blood pressure at the Final Visit/Week 26 of the open-label phase represented their Baseline blood pressure for the double-blind reversal phase. (NCT00696384)
Timeframe: Double-blind Baseline (Week 26) and Week 32.

Intervention	mmHg (Least Squares Mean)
Azilsartan Medoxomil QD - Double Blind Reversal Phase	0.59
Placebo QD - Double Blind Reversal Phase	12.97

Change From Open Label Baseline (Week 0) in Sitting Clinic Diastolic Blood Pressure to Week 26

The change from baseline in sitting clinic diastolic blood pressure measured at final visit or week 26. (NCT00696384)
Timeframe: Baseline and Week 26.

Intervention	mmHg (Mean)
Azilsartan Medoxomil QD - Open Label Phase	-15.76

Change From Open Label Baseline (Week 0) in Sitting Clinic Systolic Blood Pressure to Week 26

The change from baseline in sitting clinic systolic blood pressure measured at final visit or week 26. (NCT00696384)
Timeframe: Baseline and Week 26.

Intervention	mmHg (Mean)
Azilsartan Medoxomil QD - Open Label Phase	-23.01

Number of Participants With Adverse Events During the Open-Label Phase

Treatment-emergent adverse events defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after last dose of study drug, or within 30 days after the last dose of study drug for serious adverse event (SAE). A SAE is defined as any untoward medical occurrence that either results in death; is life-threatening; requires hospitalization; results in persistent or significant disability/incapacity; leads to a congenital anomaly/birth defect; or is an important medical event. (NCT00696384)
Timeframe: Baseline to Week 26

Intervention	participants (Number)
	Serious Adverse Events	Treatment Emergent Adverse Events
Azilsartan Medoxomil QD - Open Label Phase	8	226

Number of Participants With Adverse Events in the Double-Blind Baseline Phase

Treatment-emergent adverse events defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after last dose of study drug, or within 30 days after the last dose of study drug for SAE. A SAE is defined as any untoward medical occurrence that either results in death; is life-threatening; requires hospitalization; results in persistent or significant disability/incapacity; leads to a congenital anomaly/birth defect; or is an important medical event. (NCT00696384)
Timeframe: Double-blind Baseline/Week 26 to Week 32

Intervention	participants (Number)
	Serious Adverse Events	Treatment Emergent Adverse Events
Azilsartan Medoxomil QD - Double Blind Reversal Phase	0	42
Placebo QD - Double Blind Reversal Phase	1	38

Adverse Metabolic Effects

Change in glucose after treatment with study medication (NCT01203852)
Timeframe: after 6-8 weeks treatment

Intervention	mg/dL (Mean)
	glucose response to metoprolol (n=365)	glucose response to chlorthalidone (n=318)
Adverse Metabolic Effects	1.02	5.12

Change in Blood Pressure From Baseline to Treatment

Response to blood pressure medication will be assessed by measuring blood pressure before and after treatment (NCT01203852)
Timeframe: after 6-8 weeks of treatment

Intervention	mmHg (Mean)
	diastolic blood pressure response	systolic blood pressure response
Chlorthalidone Only	-7.68	-13.65
Metoprolol + Chlorthalidone	-7.56	-11.70
Metorprolol Only	-7.97	-7.45

Percentage of Participants at Final Visit Who Achieve Target Systolic Blood Pressure <130 mm Hg

Systolic blood pressure is the arithmetic mean of the 3 serial sitting systolic blood pressure measurements. Percentage of participants who achieve a sitting clinic systolic blood pressure response defined as less than 130 mm Hg at Week 52. (NCT01309828)
Timeframe: Week 52

Intervention	percentage of participants (Number)
Azilsartan Medoxomil + Chlorthalidone	69.3
Olmesartan Medoxomil + Hydrochlorothiazide	78.4

Percentage of Participants at Final Visit Who Achieved Both a Clinic Systolic and Diastolic Blood Pressure Response

Systolic/diastolic blood pressure is the arithmetic mean of the 3 serial sitting systolic/diastolic blood pressure measurements. Percentage of participants who achieved both a sitting clinic systolic and diastolic blood pressure response, defined as systolic blood pressure less than 130 mm Hg and diastolic blood pressure less than 80 mm Hg at Week 52. (NCT01309828)
Timeframe: Week 52

Intervention	percentage of participants (Number)
Azilsartan Medoxomil + Chlorthalidone	58.7
Olmesartan Medoxomil + Hydrochlorothiazide	73.0

Percentage of Participants at Final Visit Who Achieved Target Diastolic Blood Pressure <80 mm Hg

Diastolic blood pressure is the arithmetic mean of the 3 serial sitting diastolic blood pressure measurements. Percentage of participants at Week 52 who achieved a sitting clinic diastolic blood pressure response, defined as less than 80 mm Hg. (NCT01309828)
Timeframe: Week 52

Intervention	percentage of participants (Number)
Azilsartan Medoxomil + Chlorthalidone	80.0
Olmesartan Medoxomil + Hydrochlorothiazide	87.8

Number of Participants With at Least 1 Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have a causal relationship with this treatment. A serious AE is defined as any untoward medical occurrence that resulted in death, was life threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, led to a congenital anomaly/birth defect or was an important medical event that may have required intervention to prevent any of items above. (NCT01309828)
Timeframe: From the first dose of open-label study drug until 14 days (or 30 days for a serious adverse event) after the last dose of open- label study drug (up to 56 weeks).

Intervention	participants (Number)
	Adverse Events	Adverse Events Leading to Discontinuation	Serious Adverse Events	Serious Adverse Events Leading to Discontinuation	Death
Azilsartan Medoxomil + Chlorthalidone	68	17	8	5	0
Olmesartan Medoxomil + Hydrochlorothiazide	58	15	9	4	1

Death From Any Cause in the Glycemia Trial.

"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years

Intervention	participants (Number)
Glycemia Trial: Intensive Control	391
Glycemia Trial: Standard Control	327

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years

Intervention	participants (Number)
Glycemia Trial: Intensive Control	503
Glycemia Trial: Standard Control	543

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years

Intervention	participants (Number)
BP Trial: Intensive Control	208
BP Trial: Standard Control	237

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Intervention	participants (Number)
Lipid Trial: Fenofibrate	291
Lipid Trial: Placebo	310

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Intervention	participants (Number)
Lipid Trial: Fenofibrate	641
Lipid Trial: Placebo	667

Stroke in the Blood Pressure Trial.

Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years

Intervention	participants (Number)
BP Trial: Intensive Control	36
BP Trial: Standard Control	62

Percentage of Participants Who Achieve a Target Clinic Diastolic Blood Pressure at Week 8

Percentage of participants who achieve a target clinic diastolic blood pressure measured at final visit or week 8, defined as less than 90 mm Hg (or less than 80 mm Hg for participants with diabetes or chronic kidney disease). Diastolic blood pressure is based on the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. (NCT01456169)
Timeframe: Week 8

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 40 mg	60.2
Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg	81.0
Azilsartan Medoxomil + Chlorthalidone 40/25 mg	85.9

Percentage of Participants Who Achieve a Target Clinic Systolic Blood Pressure at Week 8

Percentage of participants who achieve a target clinic systolic blood pressure measured at final visit or week 8, defined as less than 140 mm Hg (or less than 130 mm Hg for participants with diabetes or chronic kidney disease). Systolic blood pressure is the arithmetic mean of the 3 trough sitting Systolic blood pressure measurements. (NCT01456169)
Timeframe: Week 8

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 40 mg	35.3
Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg	62.7
Azilsartan Medoxomil + Chlorthalidone 40/25 mg	77.8

Percentage of Participants Who Achieve Both Clinic Systolic and Diastolic Blood Pressure Targets at Week 8

Percentage of participants who achieve both clinic systolic and diastolic blood pressure targets at Week 8, defined as less than 140 mm Hg (or less than 130 mm Hg for participants with diabetes or chronic kidney disease) for systolic AND less than 90 mm Hg (or less than 80 mm Hg for participants with diabetes or chronic kidney disease) for diastolic blood pressure. (NCT01456169)
Timeframe: Week 8

Intervention	percentage of participants (Number)
Azilsartan Medoxomil 40 mg	30.8
Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg	59.5
Azilsartan Medoxomil + Chlorthalidone 40/25 mg	74.1

Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

Intervention	mm Hg (Least Squares Mean)
	Baseline	Change from Baseline to Week 8
Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg	80.3	-8.5
Azilsartan Medoxomil + Chlorthalidone 40/25 mg	82.5	-10.1
Azilsartan Medoxomil 40 mg	81.9	-1.6

Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

Intervention	mm Hg (Least Squares Mean)
	Baseline	Change from Baseline to Week 8
Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg	137.0	-14.7
Azilsartan Medoxomil + Chlorthalidone 40/25 mg	138.2	-18.1
Azilsartan Medoxomil 40 mg	138.0	-2.3

Change From Baseline to Week 8 in the Mean Daytime Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in daytime (6 am to 10 pm) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. (NCT01456169)
Timeframe: Baseline and Week 8

Intervention	mm Hg (Least Squares Mean)
	Baseline	Change from Baseline to Week 8
Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg	83.6	-8.9
Azilsartan Medoxomil + Chlorthalidone 40/25 mg	85.7	-10.1
Azilsartan Medoxomil 40 mg	84.9	-1.7

Change From Baseline to Week 8 in the Mean Daytime Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in daytime (6 am to 10 pm) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm. (NCT01456169)
Timeframe: Baseline and Week 8

Intervention	mm Hg (Least Squares Mean)
	Baseline	Change from Baseline to Week 8
Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg	141.1	-15.3
Azilsartan Medoxomil + Chlorthalidone 40/25 mg	141.9	-18.2
Azilsartan Medoxomil 40 mg	141.5	-2.4

Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring

The change in the 12-hour mean diastolic blood pressure measured at final visit or Week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing. (NCT01456169)
Timeframe: Baseline and Week 8

Intervention	mm Hg (Least Squares Mean)
	Baseline	Week 8
Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg	84.2	-8.9
Azilsartan Medoxomil + Chlorthalidone 40/25 mg	86.0	-10.1
Azilsartan Medoxomil 40 mg	85.2	-1.6

Change From Baseline to Week 8 in the Mean Nighttime Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in nighttime (12 am to 6 am) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. (NCT01456169)
Timeframe: Baseline and Week 8.

Intervention	mm Hg (Least Squares Mean)
	Baseline	Change from Baseline to Week 8
Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg	70.6	-7.2
Azilsartan Medoxomil + Chlorthalidone 40/25 mg	72.9	-9.8
Azilsartan Medoxomil 40 mg	73.2	-1.6

Change From Baseline to Week 8 in the Mean Nighttime Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring

The change in nighttime (12 am to 6 am) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am. (NCT01456169)
Timeframe: Baseline and Week 8

Intervention	mm Hg (Least Squares Mean)
	Baseline	Change from Baseline to Week 8
Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg	124.2	-12.7
Azilsartan Medoxomil + Chlorthalidone 40/25 mg	126.3	-17.3
Azilsartan Medoxomil 40 mg	127.3	-2.2

Change From Baseline to Week 8 in the Mean Systolic Blood Pressure 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring

Intervention	mm Hg (Least Squares Mean)
	Baseline	Change from Baseline to Week 8
Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg	141.8	-15.4
Azilsartan Medoxomil + Chlorthalidone 40/25 mg	142.3	-18.2
Azilsartan Medoxomil 40 mg	141.6	-2.3

Change From Baseline to Week 8 in Trough Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring

Intervention	mm Hg (Least Squares Mean)
	Baseline	Change from Baseline to Week 8
Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg	83.6	-8.8
Azilsartan Medoxomil + Chlorthalidone 40/25 mg	86.0	-9.4
Azilsartan Medoxomil 40 mg	86.4	-2.2

Change From Baseline to Week 8 in Trough Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring

Intervention	mm Hg (Least Squares Mean)
	Baseline	Change from Baseline to Week 8
Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg	140.2	-14.0
Azilsartan Medoxomil + Chlorthalidone 40/25 mg	142.0	-16.6
Azilsartan Medoxomil 40 mg	143.1	-2.5

Change From Baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure

The change between trough diastolic blood pressure measured at final visit or week 8 relative to baseline Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. (NCT01456169)
Timeframe: Baseline and Week 8

Intervention	mm Hg (Least Squares Mean)
	Baseline	Change from Baseline to Week 8
Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg	87.7	-7.7
Azilsartan Medoxomil + Chlorthalidone 40/25 mg	88.8	-10.3
Azilsartan Medoxomil 40 mg	89.8	-3.2

Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure

The change between trough systolic blood pressure measured at final visit or Week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements. (NCT01456169)
Timeframe: Baseline (of the double-blind treatment period) and Week 8

Intervention	mm Hg (Least Squares Mean)
	Baseline	Change from Baseline to Week 8
Azilsartan Medoxomil + Chlorthalidone 40/12.5 mg	149.8	-15.8
Azilsartan Medoxomil + Chlorthalidone 40/25 mg	149.8	-21.1
Azilsartan Medoxomil 40 mg	150.7	-6.4